Kyle Mikson
Stock Analyst at Canaccord Genuity
(0.67)
# 3,681
Out of 4,818 analysts
75
Total ratings
19.7%
Success rate
-24.9%
Average return
Main Sectors:
Stocks Rated by Kyle Mikson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GRAL GRAIL | Initiates: Buy | $32 | $34.73 | -7.86% | 1 | Apr 21, 2025 | |
| RGEN Repligen | Maintains: Hold | $170 → $150 | $147.20 | +1.90% | 3 | Apr 16, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Buy | $3 | $1.22 | +145.90% | 8 | Apr 10, 2025 | |
| QTRX Quanterix | Maintains: Buy | $20 → $15 | $5.61 | +167.38% | 5 | Mar 18, 2025 | |
| ILMN Illumina | Maintains: Hold | $135 → $115 | $78.91 | +45.74% | 8 | Mar 11, 2025 | |
| NTRA Natera | Maintains: Buy | $180 → $195 | $151.18 | +28.99% | 8 | Feb 28, 2025 | |
| GH Guardant Health | Maintains: Buy | $42 → $60 | $46.68 | +28.53% | 5 | Feb 24, 2025 | |
| TXG 10x Genomics | Maintains: Buy | $20 → $18 | $8.33 | +116.09% | 7 | Feb 13, 2025 | |
| XGN Exagen | Maintains: Buy | $5 → $7 | $5.43 | +28.91% | 2 | Jan 3, 2025 | |
| AKYA Akoya Biosciences | Maintains: Buy | $6 → $3.5 | $1.28 | +173.44% | 3 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $1.29 | +132.56% | 4 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $1.5 → $1 | $1.19 | -15.97% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $75 | $45.70 | +64.11% | 9 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $42 | $22.73 | +84.78% | 3 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $3.5 | $0.49 | +611.96% | 2 | Mar 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $2 | $0.49 | +310.93% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $49 | $0.71 | +6,829.58% | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $3.31 | +474.02% | 1 | Jan 29, 2021 |
GRAIL
Apr 21, 2025
Initiates: Buy
Price Target: $32
Current: $34.73
Upside: -7.86%
Repligen
Apr 16, 2025
Maintains: Hold
Price Target: $170 → $150
Current: $147.20
Upside: +1.90%
Pacific Biosciences of California
Apr 10, 2025
Maintains: Buy
Price Target: $3
Current: $1.22
Upside: +145.90%
Quanterix
Mar 18, 2025
Maintains: Buy
Price Target: $20 → $15
Current: $5.61
Upside: +167.38%
Illumina
Mar 11, 2025
Maintains: Hold
Price Target: $135 → $115
Current: $78.91
Upside: +45.74%
Natera
Feb 28, 2025
Maintains: Buy
Price Target: $180 → $195
Current: $151.18
Upside: +28.99%
Guardant Health
Feb 24, 2025
Maintains: Buy
Price Target: $42 → $60
Current: $46.68
Upside: +28.53%
10x Genomics
Feb 13, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $8.33
Upside: +116.09%
Exagen
Jan 3, 2025
Maintains: Buy
Price Target: $5 → $7
Current: $5.43
Upside: +28.91%
Akoya Biosciences
Nov 15, 2024
Maintains: Buy
Price Target: $6 → $3.5
Current: $1.28
Upside: +173.44%
Nov 14, 2024
Maintains: Buy
Price Target: $3
Current: $1.29
Upside: +132.56%
Nov 13, 2024
Maintains: Hold
Price Target: $1.5 → $1
Current: $1.19
Upside: -15.97%
Nov 6, 2024
Maintains: Buy
Price Target: $95 → $75
Current: $45.70
Upside: +64.11%
Oct 29, 2024
Maintains: Buy
Price Target: $35 → $42
Current: $22.73
Upside: +84.78%
Mar 4, 2024
Reiterates: Buy
Price Target: $3.5
Current: $0.49
Upside: +611.96%
Aug 16, 2023
Maintains: Overweight
Price Target: $3 → $2
Current: $0.49
Upside: +310.93%
Mar 30, 2021
Initiates: Overweight
Price Target: $49
Current: $0.71
Upside: +6,829.58%
Jan 29, 2021
Initiates: Overweight
Price Target: $19
Current: $3.31
Upside: +474.02%